CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes
This article was originally published in The Tan Sheet
Executive Summary
Officials from FDA's drug center describe their work on the Nonprescription Safe Use Regulatory Expansion initiative and on the center's evaluation of potential solutions to the OTC drug monograph process logjam. A CDER attorneys says FDA" is working towards finalizing" an NSURE regulatory framework.
You may also be interested in...
Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.
Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
CDER has been studying ideas such as pictograms to communicate instructions on administering opioid-reversal medication, but officials can’t predict when new approaches might help enable FDA to propose regulatory changes in the US switch process.